Cargando…
Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
The purpose of this study was to identify clinician characteristics associated with higher prescription rates of long-acting injectable (LAI) antipsychotics, as well as the sources that influence medical decision-making regarding the treatment of schizophrenia. We surveyed 202 psychiatrists during s...
Autores principales: | Samalin, Ludovic, Garnier, Marion, Auclair, Candy, Llorca, Pierre-Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133930/ https://www.ncbi.nlm.nih.gov/pubmed/27869767 http://dx.doi.org/10.3390/ijms17111935 |
Ejemplares similares
-
Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
por: Llorca, Pierre Michel, et al.
Publicado: (2013) -
Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
por: Samalin, L, et al.
Publicado: (2010) -
Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011) -
Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016) -
Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)